More Videos
SPECIAL REPORT
MOST SHARED
- U.S. May Wind Up Green With Envy
- Warren Buffett to CNBC: 'I Haven't Bought American Express In Years'
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- Taking a Page from Obama's Asia Agenda in Investing
- Sustainability Indices Sprouting Up
- For Investors, The New Green Looks To Be White
- The Cost of Thanksgiving Dinner 2009
- EADS Cautious on Full-Year Forecast after Earnings Dip
- Disaster Film '2012' Drowns Rivals at Box Office
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- Warren Buffett to CNBC: 'I Haven't Bought American Express In Years'
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- Stronger Yuan Needed for Global Rebalancing: IMF Chief
- Washington Not Trying to Contain China: Obama
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- Quiz: How Much Do You Know About Green?
- Citi Rejects Terra Firma's Latest Bid to Save EMI: Report
- JP Morgan to Bid Over $3 Billion for Cazenove Stake
- Analysis: APEC Nations Back Face-Saving Climate Plan
- BlackRock: Central Banks To Be Net Buyers of Gold
- GM to Start Repaying $6.7 Billion US Government Loan
RSS FEED
Pharma's Market
Text Size 
 |
George Widman / AP The Horsham, Pa., offices of Teva Pharmaceuticals North America are shown Monday, July 25, 2005. In a deal that will create the world's largest generic drug company, Teva Pharmaceutical Industries Ltd. said Monday it is acquiring rival Ivax Corp. for about $7.4 billion (6.13 billion euros) in cash and stock. Ivax shares climbed 10 percent in morning trading. (AP Photo/George Widman) |
The price is $66.50 a share, which really isn't much a premium based on Thursday's closing price.
But it's a huge markup from where BRL's [BRL
Loading...
()
]stock was sitting earlier this week before the rumors and media reports started swirling about a deal being in the works.
Barr's Chairman and CEO Bruce Downey told me Teva's CEO Schlomo Yanai made the first move. But it didn't happen in a long-distance phone call from Tel Aviv to New Jersey. They say they were at an industry conference in Palm Beach outside some burger joint when the subject came up.
On the conference call this morning during the question and answer period, one analyst (I'd like to give him credit for his sense of humor, but I can't remember who it was and because I'm under deadline I don't have time to go back and listen to the replay) joked to Mr. Downey, "You got reimbursed for lunch in this deal." The CEO shot back, "And I can afford the next one, too."
I got to know Mr. Downey when he was fighting to win Food and Drug Administration approval of over-the-counter sales for the somewhat controversial Plan B or so-called "Morning After Pill". The social implications of its eventual behind-the-counter approval were much bigger than the financial implications for BRL.
But Mr. Downey maintained he personally believed the drug should be more easily accessible and that he was on a mission to make it happen. In the first quarter of this year, BRL took in nearly 600 million bucks. Less than a hundred million of that was from a number of proprietary products, which includes Plan B.
He also volunteered during his interview with me on CNBC this morning that during his tenure he'd been approached 12 times about doing a deal like this one. A dozen offers! Wow. Both Downey and Yanai said they think the generic drug sector will continue to consolidate. Among the American players still out there are Mylan Labs[MYL
Loading...
()
], Watson Pharmaceuticals[WPI
Loading...
()
] and King Pharmaceuticals[KG
Loading...
()
], just to name a few.
What's pushing the companies together? Yes, tens of billions of dollars worth of brand-name drugs are going generic. But there are so many generic drug companies around the world that start making the same plain-wrap version of a former blockbuster, prices and profit margins fall even more. And David Maris, who used to cover the sector at Bank of America but now works for a hedge fund, told me over the phone this morning that something new is at work, too.
The likes of Wal-Mart [
Loading...
()
]with its $4 generic drug prescriptions and CVS Caremark,[CVS
Loading...
()
] which Maris said is now responsible for 20 percent of the drugs purchased in the U.S., are driving hard bargains.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes